SMT Bio Co., Ltd.
π°π·South Korea
Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer
Phase 2
Recruiting
- Conditions
- Biliary Tract Cancer
- Interventions
- Drug: SMT-NK inj.+PembrolizumabDrug: Pembrolizumab
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- SMT bio Co., Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT05429697
- Locations
- π°π·
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
π°π·Severance Hospital, Seoul, Korea, Republic of
π°π·Gangnam Severance Hospital, Seoul, Korea, Republic of
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
Phase 1
Completed
- Conditions
- Biliary Tract Cancer
- Interventions
- Biological: 'SMT-NK' Inj (allogeneic Natural Killer cell)Drug: Pembrolizumab Injection [Keytruda]
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- SMT bio Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03937895
- Locations
- π°π·
Gangnam Severance Hospital, Seoul, Korea, Republic of
π°π·Severance Hospital, Seoul, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath